Biomarker & Intervention Discovery

Hepatitis B

This page lists 11 druggable gene targets, 54 approved or trial-tested drug candidates and 15 recent clinical trials for Hepatitis B, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

NIH funding$387MFY2025 · RCDC estimate
Spontaneous remissionChronic HBV: spontaneous HBsAg loss (functional cure) in 0.5-2%/year on antiviral therapy, 0.1-0.5%/year without…
Best-intervention remissionCurrent antivirals (entecavir, tenofovir): suppress HBV DNA to undetectable in >95% but do not clear cccDNA reservoir…
Gap sizeVery large — suppressive therapy prevents cirrhosis but does not cure; functional cure rate on current therapy is very…
Primary barrierbiological + access
Full remission profile →
Research Tracker Chronic Disease Interventions Hepatitis B

Remission & chronicity

Spontaneous remission
Chronic HBV: spontaneous HBsAg loss (functional cure) in 0.5-2%/year on antiviral therapy, 0.1-0.5%/year without treatment; HBeAg seroconversion spontaneous in 5-10%/year; progression to cirrhosis in 20-25% of untreated chronic HBV over 20 years
Best-intervention remission
Current antivirals (entecavir, tenofovir): suppress HBV DNA to undetectable in >95% but do not clear cccDNA reservoir; functional cure (HBsAg loss) in 1-3%/year on antiviral; combination anti-HBsAg approaches in trials showing 20-40% functional cure rates at 48 weeks
Gap size
Very large — suppressive therapy prevents cirrhosis but does not cure; functional cure rate on current therapy is very low; treatment gap in LMIC enormous (only 30% of eligible patients treated globally)
Primary barrier
biological + access
The cccDNA reservoir in hepatocytes cannot be cleared by current antivirals; cure requires either HBsAg clearance or cccDNA elimination; 296 million people with chronic HBV globally, only ~30% on treatment; HBV vaccination has transformed prevention but treatment of existing infection remains suboptimal

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

CD274 200DDX58 2IFNAR1 20IFNL3 25PDCD1 52SLC10A1 194STAT1 197TENT4A 3TENT4B 2TLR7 187TLR8 199

CD274

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ATEZOLIZUMAB ? unclear Mechanistic DGIdb
DURVALUMAB ↓ inhibits Mechanistic DGIdb
PEMETREXED DISODIUM ? unclear Mechanistic DGIdb
BETIFISOLIMAB ? unclear Mechanistic DGIdb
AVELUMAB ? unclear Mechanistic DGIdb
SOCAZOLIMAB ↓ inhibits Mechanistic DGIdb
NIVOLUMAB ? unclear Mechanistic DGIdb
COSIBELIMAB ? unclear Mechanistic DGIdb
DANBURSTOTUG ↓ inhibits Mechanistic DGIdb
ENVAFOLIMAB ? unclear Mechanistic DGIdb
PACMILIMAB ~ modulates Mechanistic DGIdb
CA-170 ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
TISLELIZUMAB ? unclear Mechanistic DGIdb
ERFONRILIMAB ↓ inhibits Mechanistic DGIdb
TREMELIMUMAB ? unclear Mechanistic DGIdb
ANTI-PD-L1 MONOCLONAL ANTIBODY FAZ053 ? unclear Mechanistic DGIdb
BINTRAFUSP ALFA ? unclear Mechanistic DGIdb
IPILIMUMAB ? unclear Mechanistic DGIdb
CEMIPLIMAB ? unclear Mechanistic DGIdb
ADEBRELIMAB ↓ inhibits Mechanistic DGIdb
SUGEMALIMAB ~ modulates Mechanistic DGIdb
LODAPOLIMAB ? unclear Mechanistic DGIdb
INCB-086550 ↓ inhibits Mechanistic DGIdb
PIDILIZUMAB ? unclear Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
ANTI-PD-L1 MONOCLONAL ANTIBODY MDX-1105 ? unclear Mechanistic DGIdb
PENPULIMAB ? unclear Mechanistic DGIdb
PEMBROLIZUMAB ? unclear Mechanistic DGIdb
ANTI-LAG-3/PD-L1 BISPECIFIC ANTIBODY FS118 ? unclear Mechanistic DGIdb
CHEMBL3582257 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL3582256 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL3582255 ↓ inhibits Mechanistic 1010.0 nM (IC50) ChEMBL
CHEMBL3582254 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL3582253 ↓ inhibits Mechanistic 110.0 nM (IC50) ChEMBL
CHEMBL3582252 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL4081869 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL4099869 ↓ inhibits Mechanistic 146.0 nM (IC50) ChEMBL
CHEMBL4089730 ↓ inhibits Mechanistic 18.0 nM (IC50) ChEMBL
CHEMBL4061613 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL

Showing top 40 of 200 agents ranked by evidence tier.

DDX58

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
INARIGIVIR SOPROXIL ? unclear Mechanistic DGIdb
SLR14 ↑ activates Mechanistic DGIdb

IFNAR1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
INTERFERON ALFA-N3 ↑ activates Mechanistic DGIdb
INTERFERON BETA-1A ↑ activates Mechanistic DGIdb
INTERFERON ALFA-N1 ? unclear Mechanistic DGIdb
ANIFROLUMAB ? unclear Mechanistic DGIdb
INTERFERON BETA ? unclear Mechanistic DGIdb
PEGINTERFERON ALFA-2A ↑ activates Mechanistic DGIdb
PEGINTERFERON BETA-1A ↑ activates Mechanistic DGIdb
INTERFERON ALFA-2A ↑ activates Mechanistic DGIdb
SIFALIMUMAB ? unclear Mechanistic DGIdb
INTERFERON-ALPHA ? unclear Mechanistic DGIdb
INTERFERON ALFACON-1 ↑ activates Mechanistic DGIdb
IFN-Β ↑ activates Mechanistic DGIdb
ALBINTERFERON ALFA-2B ↑ activates Mechanistic DGIdb
PEGINTERFERON ALFACON-1 ? unclear Mechanistic DGIdb
GLATIRAMER ? unclear Mechanistic DGIdb
INTERFERON BETA-1B ↑ activates Mechanistic DGIdb
PEGINTERFERON ALFA-2B ↑ activates Mechanistic DGIdb
INTERFERON ALFA-2B ↑ activates Mechanistic DGIdb
ROPEGINTERFERON ALFA-2B ~ modulates Mechanistic DGIdb
CHEMBL1617534 ↓ inhibits Mechanistic 4000.0 nM (Kd) ChEMBL

IFNL3

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
GRAZOPREVIR ? unclear Mechanistic DGIdb
TELAPREVIR ? unclear Mechanistic DGIdb
RITONAVIR ? unclear Mechanistic DGIdb
ASUNAPREVIR ? unclear Mechanistic DGIdb
FALDAPREVIR ? unclear Mechanistic DGIdb
BOCEPREVIR ? unclear Mechanistic DGIdb
LEDIPASVIR ? unclear Mechanistic DGIdb
INTERFERON ALFA-N1 ? unclear Mechanistic DGIdb
OMBITASVIR/PARITAPREVIR/RITONAVIR ? unclear Mechanistic DGIdb
OMBITASVIR ? unclear Mechanistic DGIdb
ATORVASTATIN ? unclear Mechanistic DGIdb
ELBASVIR ? unclear Mechanistic DGIdb
SOFOSBUVIR ? unclear Mechanistic DGIdb
SOFOSBUVIR/VELPATASVIR ? unclear Mechanistic DGIdb
PEGINTERFERON ALFA-2B ? unclear Mechanistic DGIdb
DELEOBUVIR ? unclear Mechanistic DGIdb
VOXILAPREVIR ? unclear Mechanistic DGIdb
DASABUVIR ? unclear Mechanistic DGIdb
PEGINTERFERON ALFA-2A ? unclear Mechanistic DGIdb
SOFOSBUVIR / VELPATASVIR / VOXILAPREVIR ? unclear Mechanistic DGIdb
ELBASVIR/GRAZOPREVIR ? unclear Mechanistic DGIdb
DACLATASVIR ? unclear Mechanistic DGIdb
PARITAPREVIR ? unclear Mechanistic DGIdb
SIMEPREVIR ? unclear Mechanistic DGIdb
VELPATASVIR ? unclear Mechanistic DGIdb

PDCD1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CAMRELIZUMAB ↓ inhibits Mechanistic DGIdb
AMP-224 ? unclear Mechanistic DGIdb
PEMBROLIZUMAB ↓ inhibits Mechanistic DGIdb
SERPLULIMAB ? unclear Mechanistic DGIdb
ENLONSTOBART ? unclear Mechanistic DGIdb
CEMIPLIMAB ↓ inhibits Mechanistic DGIdb
CT-011 ? unclear Mechanistic DGIdb
SASANLIMAB ? unclear Mechanistic DGIdb
PUCOTENLIMAB ↓ inhibits Mechanistic DGIdb
TISLELIZUMAB ? unclear Mechanistic DGIdb
TEBOTELIMAB ↓ inhibits Mechanistic DGIdb
CADONILIMAB ? unclear Mechanistic DGIdb
SPARTALIZUMAB ? unclear Mechanistic DGIdb
MEDI0680 ? unclear Mechanistic DGIdb
AUNP-12 ? unclear Mechanistic DGIdb
DOSTARLIMAB ? unclear Mechanistic DGIdb
TORIPALIMAB ↓ inhibits Mechanistic DGIdb
CC-90006 ? unclear Mechanistic DGIdb
CETRELIMAB ↓ inhibits Mechanistic DGIdb
PROGRAMMED CELL DEATH 1 LIGAND 1 ? unclear Mechanistic DGIdb
ANTI-PD-1 MONOCLONAL ANTIBODY SYM021 ? unclear Mechanistic DGIdb
CS-1003 ↓ inhibits Mechanistic DGIdb
EZABENLIMAB ? unclear Mechanistic DGIdb
PROLGOLIMAB ? unclear Mechanistic DGIdb
LIPUSTOBART ? unclear Mechanistic DGIdb
PENPULIMAB ↓ inhibits Mechanistic DGIdb
BALSTILIMAB ? unclear Mechanistic DGIdb
GEPTANOLIMAB ? unclear Mechanistic DGIdb
IVONESCIMAB ? unclear Mechanistic DGIdb
SINTILIMAB ? unclear Mechanistic DGIdb
LORIGERLIMAB ? unclear Mechanistic DGIdb
FINOTONLIMAB ↓ inhibits Mechanistic DGIdb
RETIFANLIMAB ? unclear Mechanistic DGIdb
PUCOLENTIMAB ? unclear Mechanistic DGIdb
BINTRAFUSP ALFA ? unclear Mechanistic DGIdb
IPAROMLIMAB ? unclear Mechanistic DGIdb
PIMIVALIMAB ↓ inhibits Mechanistic DGIdb
VUDALIMAB ? unclear Mechanistic DGIdb
APL-501 ↓ inhibits Mechanistic DGIdb
ZIMBERELIMAB ↓ inhibits Mechanistic DGIdb

Showing top 40 of 52 agents ranked by evidence tier.

SLC10A1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
MYRCLUDEX B ↓ inhibits Mechanistic DGIdb
BULEVIRTIDE ACETATE ↓ inhibits Mechanistic DGIdb
DEXPROPRANOLOL ↓ inhibits Mechanistic DGIdb
URSODIOL ↓ inhibits Mechanistic 3600.0 nM (IC50) DGIdb
MARALIXIBAT ? unclear Mechanistic DGIdb
PROPRANOLOL HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
BULEVIRTIDE ? unclear Mechanistic DGIdb
HEPALATIDE ↓ inhibits Mechanistic DGIdb
PRAVASTATIN SODIUM ? unclear Mechanistic DGIdb
ROSUVASTATIN ? unclear Mechanistic DGIdb
CYCLOSPORINE ↓ inhibits Mechanistic 1000.0 nM (IC50) DGIdb
IRBESARTAN ↓ inhibits Mechanistic 30000.0 nM (IC50) DGIdb
CHEMBL185179 ↓ inhibits Mechanistic 1600.0 nM (IC50) ChEMBL
CHEMBL182301 ↓ inhibits Mechanistic 300.0 nM (IC50) ChEMBL
CHEMBL185033 ↓ inhibits Mechanistic 700.0 nM (IC50) ChEMBL
CHEMBL184982 ↓ inhibits Mechanistic 200.0 nM (IC50) ChEMBL
CHEMBL367757 ↓ inhibits Mechanistic 300.0 nM (IC50) ChEMBL
CHEMBL182671 ↓ inhibits Mechanistic 300.0 nM (IC50) ChEMBL
CHEMBL179911 ↓ inhibits Mechanistic 8600.0 nM (IC50) ChEMBL
CHEMBL182965 ↓ inhibits Mechanistic 63000.0 nM (IC50) ChEMBL
CHEMBL362668 ↓ inhibits Mechanistic 3400.0 nM (IC50) ChEMBL
CHEMBL182697 ↓ inhibits Mechanistic 220.0 nM (IC50) ChEMBL
FUROSEMIDE ↓ inhibits Mechanistic 15000.0 nM (IC50) ChEMBL
TAUROCHOLIC ACID ↓ inhibits Mechanistic 5300.0 nM (IC50) ChEMBL
PROPRANOLOL ↓ inhibits Mechanistic 5500.0 nM (IC50) ChEMBL
LEVOPROPRANOLOL ↓ inhibits Mechanistic 6100.0 nM (IC50) ChEMBL
SULFOBROMOPHTHALEIN SODIUM ↓ inhibits Mechanistic 7300.0 nM (IC50) ChEMBL
ROSIGLITAZONE ↓ inhibits Mechanistic 5100.0 nM (IC50) ChEMBL
SULFASALAZINE ↓ inhibits Mechanistic 9600.0 nM (IC50) ChEMBL
TIRATRICOL ↓ inhibits Mechanistic 6900.0 nM (IC50) ChEMBL
ZAFIRLUKAST ↓ inhibits Mechanistic 6500.0 nM (IC50) ChEMBL
FLUVASTATIN ↓ inhibits Mechanistic 40000.0 nM (IC50) ChEMBL
FASIGLIFAM ↓ inhibits Mechanistic 2000.0 nM (IC50) ChEMBL
CHEMBL4781848 ↓ inhibits Mechanistic 66.0 nM (IC50) ChEMBL
CHEMBL4849233 ↓ inhibits Mechanistic 14.0 nM (IC50) ChEMBL
CHEMBL4864019 ↓ inhibits Mechanistic 14.0 nM (IC50) ChEMBL
CHEMBL4869726 ↓ inhibits Mechanistic 14.0 nM (IC50) ChEMBL
CHEMBL4875540 ↓ inhibits Mechanistic 14.0 nM (IC50) ChEMBL
CHEMBL4861143 ↓ inhibits Mechanistic 14.0 nM (IC50) ChEMBL
CHEMBL4855155 ↓ inhibits Mechanistic 109.2 nM (IC50) ChEMBL

Showing top 40 of 194 agents ranked by evidence tier.

STAT1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PICOPLATIN ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL85826 ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
ZDZ-553 ↓ inhibits Mechanistic DGIdb
GARCINOL ? unclear Mechanistic 16900.0 nM (Kd) DGIdb
IPRIFLAVONE ? unclear Mechanistic 418.0 nM (EC50) DGIdb
GUTTIFERONE K ? unclear Mechanistic 20600.0 nM (Kd) DGIdb
CHEMBL392556 ↓ inhibits Mechanistic 42000.0 nM (IC50) ChEMBL
CHEMBL1447780 ↓ inhibits Mechanistic 13806.0 nM (IC50) ChEMBL
CHEMBL1396735 ↓ inhibits Mechanistic 18704.0 nM (IC50) ChEMBL
CHEMBL1479764 ↓ inhibits Mechanistic 40181.0 nM (IC50) ChEMBL
CHEMBL1355238 ↓ inhibits Mechanistic 13622.0 nM (IC50) ChEMBL
CHEMBL1299252 ↓ inhibits Mechanistic 21682.0 nM (IC50) ChEMBL
CHEMBL1353893 ↓ inhibits Mechanistic 27982.0 nM (IC50) ChEMBL
CHEMBL1515498 ↓ inhibits Mechanistic 16622.0 nM (IC50) ChEMBL
CHEMBL1324820 ↓ inhibits Mechanistic 12169.0 nM (IC50) ChEMBL
CHEMBL1496634 ↓ inhibits Mechanistic 32269.0 nM (IC50) ChEMBL
CHEMBL1354334 ↓ inhibits Mechanistic 25643.0 nM (IC50) ChEMBL
CHEMBL1424535 ↓ inhibits Mechanistic 30035.0 nM (IC50) ChEMBL
CHEMBL1340469 ↓ inhibits Mechanistic 18500.0 nM (IC50) ChEMBL
CHEMBL1986725 ↓ inhibits Mechanistic 10480.0 nM (IC50) ChEMBL
CHEMBL1420733 ↓ inhibits Mechanistic 9385.0 nM (IC50) ChEMBL
CHEMBL1487321 ↓ inhibits Mechanistic 11870.0 nM (IC50) ChEMBL
CHEMBL1607286 ↓ inhibits Mechanistic 9576.0 nM (IC50) ChEMBL
CHEMBL1382249 ↓ inhibits Mechanistic 14050.0 nM (IC50) ChEMBL
CHEMBL1539189 ↓ inhibits Mechanistic 21140.0 nM (IC50) ChEMBL
CHEMBL1461002 ↓ inhibits Mechanistic 14840.0 nM (IC50) ChEMBL
CHEMBL1578386 ↓ inhibits Mechanistic 17830.0 nM (IC50) ChEMBL
CHEMBL1518821 ↓ inhibits Mechanistic 4423.0 nM (IC50) ChEMBL
CHEMBL1479604 ↓ inhibits Mechanistic 11420.0 nM (IC50) ChEMBL
CHEMBL1568022 ↓ inhibits Mechanistic 16860.0 nM (IC50) ChEMBL
CHEMBL1492504 ↓ inhibits Mechanistic 26580.0 nM (IC50) ChEMBL
CHEMBL1462729 ↓ inhibits Mechanistic 13330.0 nM (IC50) ChEMBL
CHEMBL1541307 ↓ inhibits Mechanistic 8427.0 nM (IC50) ChEMBL
CHEMBL1502512 ↓ inhibits Mechanistic 6702.0 nM (IC50) ChEMBL
CHEMBL1375338 ↓ inhibits Mechanistic 12050.0 nM (IC50) ChEMBL
CHEMBL1370681 ↓ inhibits Mechanistic 10650.0 nM (IC50) ChEMBL
CHEMBL1371761 ↓ inhibits Mechanistic 16820.0 nM (IC50) ChEMBL
CHEMBL1465899 ↓ inhibits Mechanistic 11090.0 nM (IC50) ChEMBL
CHEMBL1545160 ↓ inhibits Mechanistic 23610.0 nM (IC50) ChEMBL

Showing top 40 of 197 agents ranked by evidence tier.

TENT4A

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
GEMCITABINE ? unclear Mechanistic DGIdb
CHEMBL5573474 ↓ inhibits Mechanistic 498.0 nM (IC50) ChEMBL
CHEMBL6143667 ↓ inhibits Mechanistic 1100.0 nM (IC50) ChEMBL

TENT4B

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CHEMBL5573474 ↓ inhibits Mechanistic 94.0 nM (IC50) ChEMBL
CHEMBL6143667 ↓ inhibits Mechanistic 850.0 nM (IC50) ChEMBL

TLR7

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
GSK2245035 ↑ activates Mechanistic DGIdb
TELRATOLIMOD ? unclear Mechanistic DGIdb
HYDROXYCHLOROQUINE ↓ inhibits Mechanistic DGIdb
852A ↑ activates Mechanistic DGIdb
RESIQUIMOD ↑ activates Mechanistic 260.1 nM (EC50) DGIdb
IMIQUIMOD ↑ activates Mechanistic 2120.0 nM (EC50) DGIdb
AZD-8848 ↑ activates Mechanistic DGIdb
TLR7 AGONIST 852A ? unclear Mechanistic DGIdb
AFIMETORAN ↓ inhibits Mechanistic DGIdb
COMPOUND 27 [WO2019226977A1] ↑ activates Mechanistic DGIdb
VESATOLIMOD ↑ activates Mechanistic 290.0 nM (EC50) DGIdb
ISATORIBINE ? unclear Mechanistic DGIdb
RG-7795 ? unclear Mechanistic DGIdb
COMPOUND 10A [PMID: 31283223] ↓ inhibits Mechanistic DGIdb
RESIQUIMOD PEGOL ? unclear Mechanistic DGIdb
LOXORIBINE ↑ activates Mechanistic DGIdb
ENPATORAN ↓ inhibits Mechanistic DGIdb
GSK-2245035 ↑ activates Mechanistic DGIdb
BAZLITORAN ↓ inhibits Mechanistic DGIdb
HYDROXYCHLOROQUINE SULFATE ↓ inhibits Mechanistic DGIdb
GURETOLIMOD ? unclear Mechanistic DGIdb
CHLOROQUINE ? unclear Mechanistic DGIdb
CPG-52852 ? unclear Mechanistic 2657.0 nM (EC50) Open Targets
CHEMBL470427 ↓ inhibits Mechanistic 25000.0 nM (IC50) ChEMBL
CHEMBL512499 ↓ inhibits Mechanistic 7500.0 nM (IC50) ChEMBL
CHEMBL519690 ↑ activates Mechanistic 10.0 nM (EC50) ChEMBL
CHEMBL483597 ↑ activates Mechanistic 10.0 nM (EC50) ChEMBL
CHEMBL484765 ↑ activates Mechanistic 5.0 nM (EC50) ChEMBL
CHEMBL215536 ↑ activates Mechanistic 790.0 nM (EC50) ChEMBL
CHEMBL213396 ↑ activates Mechanistic 3200.0 nM (EC50) ChEMBL
CHEMBL211891 ↑ activates Mechanistic 4400.0 nM (EC50) ChEMBL
CHEMBL519685 ↑ activates Mechanistic 100.0 nM (EC50) ChEMBL
CHEMBL150961 ↑ activates Mechanistic 63.7 nM (EC50) ChEMBL
CHEMBL1089862 ↑ activates Mechanistic 609.1 nM (EC50) ChEMBL
CHEMBL1089863 ↑ activates Mechanistic 51.5 nM (EC50) ChEMBL
CHEMBL1090529 ↑ activates Mechanistic 72.9 nM (EC50) ChEMBL
CHEMBL1089220 ↑ activates Mechanistic 466.8 nM (EC50) ChEMBL
CHEMBL1089224 ↑ activates Mechanistic 50.1 nM (EC50) ChEMBL
CHEMBL1089225 ↑ activates Mechanistic 10.3 nM (EC50) ChEMBL
CHEMBL1089226 ↑ activates Mechanistic 75.0 nM (EC50) ChEMBL

Showing top 40 of 187 agents ranked by evidence tier.

TLR8

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
RESIQUIMOD ↑ activates Mechanistic 6400.0 nM (EC50) DGIdb
TELRATOLIMOD ↑ activates Mechanistic DGIdb
SELGANTOLIMOD ↑ activates Mechanistic DGIdb
3M-002 ↑ activates Mechanistic DGIdb
CU-CPT8M ↓ inhibits Mechanistic DGIdb
AFIMETORAN ↓ inhibits Mechanistic DGIdb
COMPOUND 15 [PMID: 35450354] ↓ inhibits Mechanistic DGIdb
BAZLITORAN ↓ inhibits Mechanistic DGIdb
ENPATORAN ↓ inhibits Mechanistic DGIdb
RESIQUIMOD PEGOL ? unclear Mechanistic DGIdb
COMPOUND 12P [LARSON ET AL., 2017] ↑ activates Mechanistic DGIdb
MOTOLIMOD ↑ activates Mechanistic DGIdb
CHEMBL2018897 ↓ inhibits Mechanistic 4780.0 nM (IC50) ChEMBL
CHEMBL2018888 ↓ inhibits Mechanistic 3200.0 nM (IC50) ChEMBL
CHEMBL2018889 ↓ inhibits Mechanistic 15630.0 nM (IC50) ChEMBL
CHEMBL2018890 ↓ inhibits Mechanistic 10920.0 nM (IC50) ChEMBL
CHEMBL2018891 ↓ inhibits Mechanistic 4650.0 nM (IC50) ChEMBL
CHEMBL512901 ↑ activates Mechanistic 1320.0 nM (EC50) ChEMBL
CHEMBL2177867 ↑ activates Mechanistic 3370.0 nM (EC50) ChEMBL
CHEMBL2177866 ↑ activates Mechanistic 850.0 nM (EC50) ChEMBL
CHEMBL2177865 ↑ activates Mechanistic 370.0 nM (EC50) ChEMBL
CHEMBL2177864 ↑ activates Mechanistic 2250.0 nM (EC50) ChEMBL
CHEMBL2177887 ↑ activates Mechanistic 4270.0 nM (EC50) ChEMBL
CHEMBL2177883 ↑ activates Mechanistic 7640.0 nM (EC50) ChEMBL
CHEMBL2177880 ↑ activates Mechanistic 4990.0 nM (EC50) ChEMBL
CHEMBL2177878 ↑ activates Mechanistic 9010.0 nM (EC50) ChEMBL
CHEMBL2177876 ↑ activates Mechanistic 5810.0 nM (EC50) ChEMBL
CHEMBL2177875 ↑ activates Mechanistic 9380.0 nM (EC50) ChEMBL
CHEMBL2177874 ↑ activates Mechanistic 1680.0 nM (EC50) ChEMBL
CHEMBL2177872 ↑ activates Mechanistic 9790.0 nM (EC50) ChEMBL
CHEMBL2177871 ↑ activates Mechanistic 4910.0 nM (EC50) ChEMBL
CHEMBL2177870 ↑ activates Mechanistic 10580.0 nM (EC50) ChEMBL
CHEMBL2177869 ↑ activates Mechanistic 6930.0 nM (EC50) ChEMBL
CHEMBL2216760 ↑ activates Mechanistic 41300.0 nM (EC50) ChEMBL
CHEMBL1082983 ↑ activates Mechanistic 100.0 nM (EC50) ChEMBL
CHEMBL2419274 ↑ activates Mechanistic 46200.0 nM (EC50) ChEMBL
CHEMBL2419471 ↑ activates Mechanistic 24400.0 nM (EC50) ChEMBL
CHEMBL2419475 ↑ activates Mechanistic 1600.0 nM (EC50) ChEMBL
VESATOLIMOD ↑ activates Mechanistic 9000.0 nM (EC50) ChEMBL
CHEMBL3116315 ↑ activates Mechanistic 31000.0 nM (EC50) ChEMBL

Showing top 40 of 199 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Hepatitis B: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE) Recruiting
NCT06650852 Phase: 2 Started: 2024-10-31

This Phase 2, randomized, double-blind study will evaluate the clinical efficacy and safety of the combination therapy of BRII-179, BRII-835, plus PEG-IFNα compared to PEG-IFNα in adult participants with chronic HBV infection without cirrhosis receiving neucloes(t)ide reverse transcriptase inhibitor...

The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort Recruiting
NCT04970836 Phase: N/A Started: 2021-08-01

This prospective cohort study aims to provide the evidence-based clinical guide to help decide the revaccination doses of hepatitis B vaccine that the high-risk young adults without hepatitis B seroprotective antibodies (anti-HBs titer\<10 mIU/mL) need to take.

Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) Completed
NCT06491563 Phase: 2 Started: 2024-08-06

This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.

Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients Completed
NCT05490836 Phase: N/A Started: 2022-09-01

The study is aimed to explore the safety and efficacy of the pulse usage , comparing to continuous usage, of Peginterferon alfa-2b Injection (PEG IFN α-2b) Combined With tenofovir alafenamide (TAF) in treatment of naive chronic hepatitis B patients with HBeAg negative.

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients Completed
NCT05970289 Phase: 2 Started: 2023-08-22

This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.

Efficacy of Tenofovir Disoproxil on Mother-to-child Transmission of HBV in Tokombéré, Cameroon in Pregnant Women Active Not Recruiting
NCT05403047 Phase: 4 Started: 2023-08-22

Pregnant women with HBeAg-positive viral hepatitis b or high viral load will receive Tenofovir disoproxil fumarate (TDF) from the 28th week of amenorrhoea until 6 weeks after delivery. Their newborns will receive the hepatitis B vaccine, starting with one dose at birth and followed by three booster ...

A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults Active Not Recruiting
NCT07059403 Phase: 1 Started: 2025-08-19

This is a randomized, double-blind, placebo-controlled, multiple-ascending-dose study of SN2001 in healthy adult subjects. The study is designed to evaluate the safety, tolerability and immunogenicity of SN2001.

HepB mAb19 in Individuals With Chronic Hepatitis B Infection Active Not Recruiting
NCT05856890 Phase: 1 Started: 2024-04-25

This is a first-in-human, placebo-controlled, single dose, dose-escalation phase 1 study to evaluate the safety, pharmacokinetics and antiviral activity of a highly potent neutralizing anti-HBV monoclonal antibody (mAb), HepB mAb19, which targets the S-protein in individuals with chronic hepatitis B...

Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region Recruiting
NCT07370207 Phase: 2 Started: 2026-03-06

This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with Nucleos(t)ide Analogue (NAs).

A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults Completed
NCT06989788 Phase: 1 Started: 2025-05-06

The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of repeated administrations of AVX70371 in healthy participants.

Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study) Completed
NCT04202653 Phase: 2 Started: 2020-01-01

This study is a single-center, randomized, prospective, open-label Phase 2 Clinical trial to evaluate efficacy and safety of ETV and TQ-A3334 combinated with/without inhibitor of TQ-B2450 versus ETV alone in chronic hepatitis B patients. Patients were randomized to one of 3 different antiviral treat...

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B Active Not Recruiting
NCT06092333 Phase: 2 Started: 2025-01-31

Background: Chronic hepatitis B virus (HBV) infection affects 292 million people worldwide; 887,000 die each year from cirrhosis, liver cancer, and related issues. Treatment options are limited. Objective: To test 2 drugs (VIR-2218 and peginterferon) in people with mild or inactive HBV infection. El...

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A) Recruiting
NCT07852091 Phase: 2 Started: 2023-10-10

Hepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of HBV treatment. However, HBsAg loss can be achieved in less than 10% of...

A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B Recruiting
NCT07389044 Phase: 1 Started: 2026-02-20

This study will examine the safety and tolerability of single and multiple doses of IB-001 in two parts: Part A: SAD study in approximately 50 Healthy Volunteers (HV). Part B: MAD study in approximately 30 adult participants living with Chronic Hepatitis B (CHB). A separate exploratory, open-label, ...

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B) Recruiting
NCT07845058 Phase: 2 Started: 2023-10-10

Hepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of HBV treatment. However, HBsAg loss can be achieved in less than 10% of...

Agents Found By Disease-Level Search

Searched directly from “Hepatitis B” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 11-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

54 agents shown (approved or with trial evidence) — 52 not found by the gene-target search above.

entecavirNOT in gene-target list

Approved · 7 trials · source: ClinicalTrials.gov, Open Targets
NCT01711567 NCT01639066 NCT04536337

TelbivudineNOT in gene-target list

Approved · 5 trials · source: ClinicalTrials.gov, Open Targets
NCT03778567 NCT00805675 NCT00076336

tenofovirNOT in gene-target list

Phase 3 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT01711567 NCT01639066 NCT01639066

DTaP-IPV-HB-PRP~T vaccineNOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT00404651 NCT00404651 NCT00404651

Engerix-BNOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT02901951 NCT02434848 NCT03627507

Resiquimod gelNOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT00175435 NCT00175435 NCT00175435

TWINRIX™ ADULTNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00289744 NCT00197119

ClevudineNOT in gene-target list

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01192854 NCT00362635

AdefovirNOT in gene-target list

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01192854 NCT02366208

EngerixTM-BNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00880477 NCT00774995

Hepatitis B VaccineNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT02444611 NCT00792610

TDFNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT01320943 NCT03596697

Peginterferon alfa-2a

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02097004 NCT02714712

DTaP-IPV//PRP~T combined vaccineNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00303316 NCT00303316

Euvax B®: Hepatitis B vaccineNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT02697474 NCT02697474

TRUVADA (EMTRICITABINE + TENOFOVIR DF)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00391638

PEGASYS 180μg (Interféron pégylé alpha -2a)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00391638

Engerix TMNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00289744

287615 containing HBsAg with adjuvantsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00508833

Pneumococcal conjugate vaccine GSK1024850ANOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00463437

PrevenarNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00463437

Infanrix hexaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00463437

Infanrix IPV HibNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00463437

Infanrix pentaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00463437

Infanrix IPVNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00463437

MeningitecNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00463437

NeisVac-CNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00463437

MenitorixNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00463437

Vemlidy TabNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04906109

DA-2803 TabNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04906109

Pegyinterferon-alfa-2aNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02068365

TQ-A3334 tabletsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06160895

Twinrix™ JuniorNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00197119

Infanrix hexa VaccineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00376779

Tenofovir Disoproxil FumarateNOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00122486

Lopinavir/Ritonavir (Kaletra)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01153269

DTaP-HBV-IPV vaccineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00404651

clevudine, AdefovirNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01263002

ALG-000184NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04536337

DTPa-HBV-IPV/Hib vaccineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00880477

DTPa-IPV/Hib vaccineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00880477

IONIS-HBVRxNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02981602

Durvalumab

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT04294498

Parolee Comprehensive Care + Phone CoachNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01844414

DTPa-HBV-IPV/Hib (Infanrix-hexa™)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01457495

DTPa-IPV/Hib (Infanrix-IPV/Hib™)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01457495

HBV (Engerix™-B)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01457495

DTaP-IPV-HB-PRP~TNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00313911

Tritanrix-HepB/HibNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00313911

Engerix-B and TwinrixNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00186836

PNMINOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02421666

Telbivudine plus tenofovirNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00805675

Tenofovir disoproxil 245mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05282407

Tenofovir disoproxil fumarate 300mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05282407

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.